LOTENSIN Drug Patent Profile

✉ Email this page to a colleague

When do Lotensin patents expire, and what generic alternatives are available?

Lotensin is a drug marketed by Validus Pharms and is included in two NDAs.

The generic ingredient in LOTENSIN is benazepril hydrochloride; hydrochlorothiazide. There are fourteen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the benazepril hydrochloride; hydrochlorothiazide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Lotensin

A generic version of LOTENSIN was approved as benazepril hydrochloride; hydrochlorothiazide by ANI PHARMS on February 11^th, 2004.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for LOTENSIN?
What are the global sales for LOTENSIN?
What is Average Wholesale Price for LOTENSIN?

Summary for LOTENSIN

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	99
Clinical Trials:	13
Patent Applications:	1,963
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for LOTENSIN
What excipients (inactive ingredients) are in LOTENSIN?	LOTENSIN excipients list
DailyMed Link:	LOTENSIN at DailyMed

Drug patent expirations by year for LOTENSIN

Recent Clinical Trials for LOTENSIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Nanjing Children's Hospital	Phase 2
University of Nebraska	Phase 4
Shanghai Children's Hospital	Phase 1/Phase 2

See all LOTENSIN clinical trials

Pharmacology for LOTENSIN

Drug Class	Angiotensin Converting Enzyme Inhibitor
Mechanism of Action	Angiotensin-converting Enzyme Inhibitors
Physiological Effect	Decreased Blood Pressure

US Patents and Regulatory Information for LOTENSIN

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Validus Pharms	LOTENSIN	benazepril hydrochloride	TABLET;ORAL	019851-001	Jun 25, 1991		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Validus Pharms	LOTENSIN HCT	benazepril hydrochloride; hydrochlorothiazide	TABLET;ORAL	020033-004	May 19, 1992	AB	RX	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Validus Pharms	LOTENSIN	benazepril hydrochloride	TABLET;ORAL	019851-004	Jun 25, 1991	AB	RX	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Validus Pharms	LOTENSIN HCT	benazepril hydrochloride; hydrochlorothiazide	TABLET;ORAL	020033-003	May 19, 1992	AB	RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Validus Pharms	LOTENSIN	benazepril hydrochloride	TABLET;ORAL	019851-002	Jun 25, 1991	AB	RX	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Validus Pharms	LOTENSIN	benazepril hydrochloride	TABLET;ORAL	019851-003	Jun 25, 1991	AB	RX	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Validus Pharms	LOTENSIN HCT	benazepril hydrochloride; hydrochlorothiazide	TABLET;ORAL	020033-002	May 19, 1992	AB	RX	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for LOTENSIN

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Validus Pharms	LOTENSIN	benazepril hydrochloride	TABLET;ORAL	019851-001	Jun 25, 1991	⤷ Sign Up	⤷ Sign Up
Validus Pharms	LOTENSIN	benazepril hydrochloride	TABLET;ORAL	019851-003	Jun 25, 1991	⤷ Sign Up	⤷ Sign Up
Validus Pharms	LOTENSIN	benazepril hydrochloride	TABLET;ORAL	019851-004	Jun 25, 1991	⤷ Sign Up	⤷ Sign Up
Validus Pharms	LOTENSIN	benazepril hydrochloride	TABLET;ORAL	019851-002	Jun 25, 1991	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for LOTENSIN

See the table below for patents covering LOTENSIN around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Norway	166232		⤷ Sign Up
Spain	526889		⤷ Sign Up
Portugal	75395	PROCESS FOR PREPARATION OF NEW BENZAPIN-2-ONAS FROM PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPOUNDS	⤷ Sign Up
Spain	8700239		⤷ Sign Up
Denmark	157881		⤷ Sign Up
Japan	S59172475	3-(5-AMINOPENTYL)-AMINO-1-BENZAZEPIN-2-ONE-1- ALKANOIC ACID	⤷ Sign Up
South Africa	8400958		⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

AI Research Assistant

Questions you can ask:

Summary for LOTENSIN

Recent Clinical Trials for LOTENSIN

Pharmacology for LOTENSIN

Make Better Decisions: Try a trial or see plans & pricing